INTRODUCTION: Rozanolixizumab is indicated for the treatment of adults with generalized myasthenia gravis (MG). This retrospective, non-interventional cohort study evaluated adults with MG initiating rozanolixizumab in the USA. METHODS: (July 2023-March 2025). Enrolled patients were aged ≥ 18 years with MG diagnosis, ≥ 1 rozanolixizumab medical/pharmacy claim, and continuous enrollment/plan coverage for 12 months (baseline period) before first rozanolixizumab treatment initiation (index date). The follow-up period was from 1 day post-index to last enrollment date. Treatment patterns and healthcare resource utilization (HCRU) were assessed during baseline and follow-up. A second study (July 2023-June 2024) assessed patients for 12 months post-index who had ≥ 1 efgartigimod claim ≤ 12 months prior to index. RESULTS: The main study included 719 patients. Patients with ≥ 365 days since rozanolixizumab initiation (n = 287) started a mean (standard deviation) 2.9 (1.8) treatment cycles in Year 1. Total MG-related HCRU incidence rates per 100 person-years were 88.0 during baseline and 82.9 during follow-up, and 86.2 versus 80.8 for outpatient, 25.6 versus 17.3 for inpatient, and 24.9 versus 14.0 for emergency room visits. Approximately half (53.7%, 386/719) of patients used corticosteroids at baseline and had ≥ 3 months' follow-up. 29.0% (n = 112) tapered their dose by ≥ 5 mg, and a further 29.3% (n = 113) discontinued corticosteroids during follow-up. In patients who had ≥ 1 claim for efgartigimod before initiating rozanolixizumab (n = 26), 19.2% tapered corticosteroids by ≥ 5 mg during follow-up, and 7.7% discontinued completely. CONCLUSION: This real-world study of patients receiving rozanolixizumab in the USA showed reductions in corticosteroid use and HCRU following rozanolixizumab initiation, including in those who switched from efgartigimod. The mean number of rozanolixizumab cycles (2.9) was lower than the mean 4.1 cycles in Phase 3 studies (patients with ≥ 1 year of follow-up), demonstrating that treatment patterns in clinical practice can be individually adjusted.
Kumar et al. (Mon,) studied this question.